Matinas BioPharma appoints Murphy, Neugeboren to board of directors

Matinas BioPharma (MTNB) announced the appointment of biotech industry veterans Keith Murphy and Edward Neugeboren to its Board of Directors as independent members, effective March 11, 2025. In addition, Matthew Wikler, M.D., and Natasha Giordano stepped down from the Board on the Effective Date. Murphy will become Chair of the Nominating and Governance Committee, replacing Giordano, and become a member of the Compensation Committee and Neugeboren will become Chair of the Compensation Committee, replacing Dr. Wikler, and become a member of the Audit Committee.